Proxypharma LLB SRL
2.1 FTEThe score of Proxypharma LLB shows with a free account.
See the score- Summary? / 5
- Solvency
- Liquidity
- Interest coverage
- Profitability
- Leverage
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity -3 % Total assets -6 % Headcount (avg FTE) -5 %
Accounts of the company itself (not consolidated).
The full file covers 8 financial years; a free account shows 2. →Proxypharma LLB's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | 35,296 € | ||||
| Equity | 532,755 € | ||||
| Cash | 86,322 € | ||||
| EBITDA | 53,176 € | ||||
| Total assets | 707,554 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 24 Jul 2026
- Year ended 31 Dec 2024filed on 16 Jul 2025
- Year ended 31 Dec 2023filed on 14 Jun 2024
- Year ended 31 Dec 2022filed on 09 Jun 2023
- Year ended 31 Dec 2021filed on 20 Jun 2022
Proxypharma LLB's financial analysis
- Solvency75.3%sector median: 41.6%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Proxypharma LLB
Proxypharma LLB's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0898.752.807
- VAT number
- BE0898752807
- Peppol
- Registered · 0208:0898752807 · as of 18 Oct 2026
- Legal form
- SRL
- Incorporated
- 24 Jun 2008
- Registered office
- 5081 La Bruyère
- Size
- Micro · 2.1 FTE
- Latest accounts
- 2025 · filed on 24 Jul 2026
- Activity
- Retail sale of pharmaceutical products (NACE 47730)
Proxypharma LLB (SRL) has been based in La Bruyère since 2008, active in: retail sale of pharmaceutical products. For 2025, it reports a net profit of 35,296 € and equity of 532,755 €; its revenue is not published. With 2.1 full-time equivalents, it is a micro-enterprise by headcount. Its solvency stands at 75.3%, above the median of its sector (41.6%).
Companies similar to Proxypharma LLB
Companies in the same business, of comparable size and area, outside its group.
- License to care Retail sale of pharmaceutical products Duffel · balance sheet 702,743 €
- Boeyckens Retail sale of pharmaceutical products Vilvoorde · balance sheet 713,576 €
- Apotheek Hoegaarden Retail sale of pharmaceutical products Hoegaarden · balance sheet 737,695 €
- Pharmacie Smeets Lamproye Retail sale of pharmaceutical products Gesves · balance sheet 667,980 €
- Pharmaflor Retail sale of pharmaceutical products Namur · balance sheet 831,466 €
- Haelvoetpharma Retail sale of pharmaceutical products Evere · balance sheet 906,520 €
- BIO - Vitalpharma Retail sale of pharmaceutical products Antwerp · balance sheet 532,020 €
- Milpharma Retail sale of pharmaceutical products Riemst · balance sheet 502,955 €
Frequently asked questions about Proxypharma LLB
What is the revenue of Proxypharma LLB?
Proxypharma LLB files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Proxypharma LLB?
In Belgium, the VAT number is the company number prefixed with BE: BE0898752807 for Proxypharma LLB, if the company is VAT-registered. Its company number (CBE) is 0898.752.807.
Where is the registered office of Proxypharma LLB?
According to the CBE register, the registered office of Proxypharma LLB is in 5081 La Bruyère.
What is the equity of Proxypharma LLB?
At the close of the 2025 financial year, the equity of Proxypharma LLB amounts to 532,755 €, a solvency of 75.3% of total assets.
How many people work at Proxypharma LLB?
2.1 full-time equivalents on average according to the 2025 social balance sheet.
Who manages Proxypharma LLB?
The register lists 3 active mandates at Proxypharma LLB. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Proxypharma LLB
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →